® Phase III Study (MDS-004) Reports a Significant Improvement in Survival and Risk Reduction in Disease Progression for Patients with del(5Q) Myelodysplastic Syndromes" />
Celgene Corporation
Dec 7, 2010
PDF
Add to Briefcase

Retrospective Analysis of Clinical Data from REVLIMID® Phase III Study (MDS-004) Reports a Significant Improvement in Survival and Risk Reduction in Disease Progression for Patients with del(5Q) Myelodysplastic Syndromes

Additional Landmark Analysis Reports that Patients Achieving RBC Transfusion Independence For At Least 26 Weeks Were Associated with Longer AML-free Survival Times Compared with Non-responders

BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) --

Celgene International Sàrl (NASDAQ: CELG)today announced updated results from a retrospective analysis of a randomised, international phase III study of REVLIMID® (lenalidomide) for the treatment of patients with low/int-1 risk myelodysplastic syndromes (MDS) with a del(5q) chromosome abnormality. These results were presented during the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL.

The updated results concluded that the cumulative three-year risk of progression to acute myeloid leukaemia (AML) rate was 25.1%, and the three-year overall survival rate was 56.0% for patients receiving lenalidomide in the study.

Patients achieving red blood cell transfusion independence (RBC-TI) for at least 26 weeks were associated with 41% and 47% reductions in risk of AML progression or death (p=0.046) and death (p=0.019), respectively, compared to patients who did not achieve RBC-TI. Factors associated with an increased risk of AML progression and death were higher baseline ferritin levels, older age, and higher transfusion burden.

Additionally, a landmark analysis showed that patients achieving RBC-TI for at least 26 weeks were associated with longer AML-free survival times compared with non-responders (P = 0.021)

The retrospective analysis evaluated 138 patients with RBC transfusion-dependent low-or-int-1-risk del(5q) MDS who were randomized to receive either lenalidomide 5 mg on days 1-28 (n=69) or lenalidomide 10 mg on days 1-21 (n=69), both in 28-day cycles. Median time since diagnosis of MDS was 2.7 years (0.2-29.2 years), median RBC transfusion requirement at baseline was 6 units/8 weeks (range, 1-25 units/8 weeks), and median duration of lenalidomide treatment was 12.9 months (range, 0.3-36.7 months). First response was assessed at 16 weeks, and responders continued double-blind treatment for up to 52 weeks, until erythroid relapse or disease progression. Patients who completed 52 weeks of therapy could enter an open-label (OL) extension phase at their current lenalidomide dose. Patients receiving placebo or 5 mg lenalidomide who did not respond by week 16 or who had erythroid relapse could receive lenalidomide 5 mg or 10 mg, respectively, in the OL phase.

This analysis included data through completion of the OL phase for patients randomized in the double-blind phase to lenalidomide 5 mg and 10 mg combined. Patients randomized to placebo were excluded, as all except 11 patients crossed over to lenalidomide 5 mg after 16 weeks of treatment.

The most common grade three or higher adverse events in the 5 mg and 10 mg arms were neutropenia (74%, 51/69 and 75%, 52/69, respectively), thrombocytopenia (33%, 23/69; 41%, 28/69) and leukopenia (13%, 9/69; 9%, 6/69).

About REVLIMID®

REVLIMID® is an IMiDs® compound. REVLIMID and other IMiDs continue to be evaluated in over 100 clinical trials. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of-matter and use patents.

REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 50 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

REVLIMID is also approved in the United States, Canada and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Marketing Authorization Applications are currently being evaluated in a number of other countries.

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy.

REVLIMID is indicated for patients with transfusion-dependent anaemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Important Safety Information

WARNING: FETAL RISK, HEMATOLOGIC TOXICITY, and DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM

Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or death to a developing baby. In women of childbearing potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Women of childbearing potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid fetal exposure to lenalidomide, REVLIMID is only available under a restricted distribution program called "RevAssist®."

Information about the RevAssist program is available at www.REVLIMID.com or by calling the manufacturer's toll-free number 1-888-423-5436.

HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA)

REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors. (see DOSAGE and ADMINISTRATION)

DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM

REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with MM who were treated with REVLIMID and dexamethasone therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.

CONTRAINDICATIONS:

Pregnancy Category X:

Allergic Reactions:

WARNINGS AND PRECAUTIONS:

Fetal Risk:

Reproductive Risk and Special Prescribing Requirements (RevAssist Program):

Haematologic Toxicity--Multiple Myeloma:

Deep Vein Thrombosis:

Allergic Reactions:

Tumour Lysis Syndrome:

Tumour Flare Reaction:

DRUG INTERACTIONS:

USE IN SPECIAL POPULATIONS:

Nursing Mothers:

Geriatric Use:

Renal Impairment:

ADVERSE REACTIONS:

Multiple Myeloma

Myelodysplastic Syndromes

DOSAGE AND ADMINISTRATION:

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

About Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies that affect approximately 300,000 people worldwide. Myelodysplastic syndromes occur when blood cells remain in an immature or "blast" stage within the bone marrow and never develop into mature cells capable of performing their necessary functions. Eventually, the bone marrow may be filled with blast cells suppressing normal cell development. MDS patients must often rely on blood transfusions to manage symptoms of anaemia and fatigue and may develop life-threatening iron overload and/or toxicity from frequent transfusions, thus underscoring the critical need for new therapies targeting the cause of the condition rather than simply managing its symptoms.

About Acute Myeloid Leukaemia

Acute Myeloid Leukaemia (AML) is a cancer of myeloid blood cells that often transforms from MDS upon disease progression. AML is the proliferation of abnormal cells that accumulate in the bone marrow and interfere with all types of normal blood cell production (multi-lineage dysplasia). AML has traditionally been treated with high intensity chemotherapy, which is poorly tolerated by the majority of the patients who are afflicted - the elderly. Many of these patients may go untreated and because they are ineligible for curative therapy, life expectancy is short and often measured in weeks to months.

About Deletion 5q Chromosomal Abnormality

Chromosomal (cytogenetic) abnormalities are detected in more than half of patients with myelodysplastic syndrome (MDS), and involve a deletion in all or part of one or more specific chromosomes. The most common cytogenetic abnormalities in MDS are deletions in the long arm of chromosomes 5, 7, and 20. Another common abnormality is an extra copy of chromosome 8. A deletion involving the 5q chromosome may be involved in 20 percent to 30 percent of all MDS patients. The World Health Organization has also recently identified a unique subset of MDS patients with a "5q- Syndrome" where the only chromosomal abnormality is a specific portion of the 5q chromosome.

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements.The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports.Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.

SOURCE: Celgene International Sàrl

Celgene International Sàrl
Director of External Relations
Kevin Loth, +41 32 729 86 21